Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Robert I. Haddad(Dana-Farber Brigham Cancer Center), Lindsay Bischoff(Breast Cancer Research Foundation), Douglas W. Ball(Sidney Kimmel Comprehensive Cancer Center), Victor Bernet, Erik Blomain(Cancer Institute (WIA)), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Michael J. Campbell(UC Davis Comprehensive Cancer Center), Paxton V. Dickson(St. Jude Children's Research Hospital), Quan‐Yang Duh(Fox Chase Cancer Center), Hormoz Ehya(Fox Chase Cancer Center), Whitney Goldner(Susan Thompson Buffett Foundation), Theresa Guo(UC San Diego Health System), Megan R. Haymart(University of Michigan), Shelby Holt(Southwestern Medical Center), Jason P. Hunt(University of Utah), Andrei Iagaru(Cancer Institute (WIA)), Fouad Kandeel(City Of Hope National Medical Center), Dominick Lamonica(Dana-Farber Brigham Cancer Center), Susan J. Mandel(University of Pennsylvania), Stephanie Markovina(Barnes-Jewish Hospital), Bryan McIver(Moffitt Cancer Center), Christopher D. Raeburn(University of Colorado Cancer Center), Rod Rezaee(Cleveland Clinic), John A. Ridge(Fox Chase Cancer Center), Mara Y. Roth(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Randall P. Scheri(Cancer Institute (WIA)), Jatin P. Shah(Memorial Sloan Kettering Cancer Center), Jennifer A. Sipos(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Rebecca S. Sippel(University of Wisconsin Carbone Cancer Center), Cord Sturgeon(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Thomas N. Wang(University of Colorado Cancer Center), Lori J. Wirth(Massachusetts General Hospital), Richard J. Wong(Memorial Sloan Kettering Cancer Center), Michael W. Yeh(UCLA Jonsson Comprehensive Cancer Center), Carly J. Cassara(Pancreatic Cancer Action Network), Susan Darlow(Pancreatic Cancer Action Network)
Journal of the National Comprehensive Cancer Network
August 1, 2022
10.6004/jnccn.2022.0040
Cited by 497Open Access
Full Text

Abstract

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).

Related Papers

No related papers found

Powered by citation graph analysis